46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details

臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02797769 (ClinicalTrials.gov)	August 2015	8/6/2016	A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)	Risk of Cardiovascular Events in Patients Using Tocilizumab as Compared With Other Biologics in Multiple Large Healthcare Databases	Rheumatoid Arthritis	Drug: Other Biologics;Drug: Tocilizumab	Hoffmann-La Roche	NULL	Not yet recruiting	18 Years	N/A	Both	75000	N/A	NULL
2	NCT01932372 (ClinicalTrials.gov)	July 26, 2013	30/7/2013	Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis	XELJANZ (REGISTERED) TABLETS 5MG SPECIAL INVESTIGATION (ALL-CASES SURVEILLANCE)	Rheumatoid Arthritis	Drug: Tofacitinib (Xeljanz);Drug: Etanercept , other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc	Pfizer	NULL	Completed	N/A	N/A	All	9968		Japan
3	JPRN-UMIN000002340	2009/08/01	20/08/2009	Comparison of effects between higher dosages of infliximab and switching to other biologics for rheumatoid arthritis patients with less responsiveness to infliximab therapy (cHAMLET)		Rheumatoid Arthritis	Treatment with higher dosages of infliximab (3-10 mg/Kg) Every 2 months Follow-up to 54 weeks Treatment with one of other biologics (etanercept, adalimumab, tocilizumab) in standard protocol Follow-up to 54 weeks	Department of Rheumatosurgery, Osaka City University Medical School	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	60	Phase 4	Japan